Manikanta Murahari
Manikanta Murahari
Associate Professor at K L College of Pharmacy, Koneru Lakshmaiah University, Vijayawada
Verified email at
Cited by
Cited by
In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2
D Prasanth, M Murahari, V Chandramohan, SP Panda, LR Atmakuri, ...
Journal of Biomolecular Structure and Dynamics 39 (13), 4618-4632, 2021
An update on Drug Repurposing: Re-written saga of the drug’s fate
HS Gns, GR Saraswathy, M Murahari, M Krishnamurthy
Biomedicine & Pharmacotherapy 110, 700-716, 2019
Complexation of phytochemicals with cyclodextrin derivatives–An insight
V Suvarna, P Gujar, M Murahari
Biomedicine & Pharmacotherapy 88, 1122-1144, 2017
Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
V Suvarna, V Singh, M Murahari
European journal of pharmacology 862, 172655, 2019
Inclusion complexation of etodolac with hydroxypropyl-beta-cyclodextrin and auxiliary agents: formulation characterization and molecular modeling studies
AP Sherje, V Kulkarni, M Murahari, UY Nayak, P Bhat, V Suvarna, ...
Molecular pharmaceutics 14 (4), 1231-1242, 2017
Phytochemicals and PI3K inhibitors in cancer–An insight
V Suvarna, M Murahari, T Khan, P Chuabey, P Sangave
Frontiers in Pharmacology 8, 916, 2017
Acridone-pyrimidine hybrids-design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
M Murahari, KV Prakash, GJ Peters, YC Mayur
European journal of medicinal chemistry 139, 961-981, 2017
Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors
M Murahari, V Mahajan, S Neeladri, MS Kumar, YC Mayur
Bioorganic Chemistry 86, 583-597, 2019
Inclusion complexes of Nateglinide with HP–β–CD and L-arginine for solubility and dissolution enhancement: Preparation, characterization, and Molecular Docking Study
V Suvarna, A Kajwe, M Murahari, GV Pujar, BK Inturi, AP Sherje
Journal of Pharmaceutical Innovation 12 (2), 168-181, 2017
Identification and usage of fluorescent probes as nanoparticle contrast agents in detecting cancer
MS Murahari, MC Yergeri
Current pharmaceutical design 19 (25), 4622-4640, 2013
Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2, 4-dimethylacridones as anticancer agents
M Murahari, PS Kharkar, N Lonikar, YC Mayur
European journal of medicinal chemistry 130, 154-170, 2017
Host-guest interaction study of Efavirenz with hydroxypropyl‑β‑cyclodextrin and l‑arginine by computational simulation studies: Preparation and characterization of …
V Suvarna, S Thorat, U Nayak, A Sherje, M Murahari
Journal of Molecular Liquids 259, 55-64, 2018
Study on effect of L-arginine on solubility and dissolution of Zaltoprofen: Preparation and characterization of binary and ternary cyclodextrin inclusion complexes
AP Sherje, F Patel, M Murahari, V Suvarna, K Patel
Chemical physics letters 694, 120-128, 2018
Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies
S Santhosh, D Mukherjee, J Anbu, M Murahari, BV Teja
Journal of Microencapsulation 36 (4), 338-355, 2019
Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand-and structure-based approaches
PF Cutinho, J Roy, A Anand, R Cheluvaraj, M Murahari, HSV Chimatapu
Journal of Biomolecular Structure and Dynamics 38 (6), 1626-1648, 2020
In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (Mpro) structure of SARS-CoV-2
B Kumar, P Parasuraman, TPK Murthy, M Murahari, V Chandramohan
Journal of Biomolecular Structure and Dynamics, 1-19, 2021
Current overview on the usage of poly (ADP-ribose) polymerase (PARP) inhibitors in treating cancer
M Swamy Murahari, M C Yergeri
Clinical Cancer Drugs 1 (2), 127-148, 2014
In-silico strategies of some selected phytoconstituents from Melissa officinalis as SARS CoV-2 main protease and spike protein (COVID-19) inhibitors
D Prasanth, M Murahari, V Chandramohan, G Bhavya, A Lakshmana Rao, ...
Molecular Simulation 47 (6), 457-470, 2021
Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis
KB Suma, A Kumari, D Shetty, E Fernandes, DV Chethan, J Jays, ...
Journal of Molecular Graphics and Modelling 101, 107718, 2020
Enzyme inhibitory function and phytochemical profile of Inula discoidea using in vitro and in silico methods
E Bursal, MA Yılmaz, E Izol, F Türkan, MN Atalar, M Murahari, A Aras, ...
Biophysical Chemistry 277, 106629, 2021
The system can't perform the operation now. Try again later.
Articles 1–20